New One-Shot meningitis vaccine shows promise in large trial
NCT ID NCT04368429
First seen Jun 25, 2026 · Last updated Jun 26, 2026 · Updated 1 time
Summary
This Phase 3 trial tested a new single-dose vaccine (MenACYW) against an existing one (Menactra) in 360 healthy people aged 2 to 55. The goal was to see if the new vaccine triggers a similar or better immune response to four types of meningococcal bacteria. Results showed the new vaccine was non-inferior, meaning it worked as well as the current vaccine, with a similar safety profile.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Meningococcal conjugate vaccine (MenACYW)
- What this could lead to
- If successful, this could provide a new option for a single-dose vaccine to protect against four types of meningococcal bacteria that cause meningitis and bloodstream infections.
- What could go wrong
- This is a completed Phase 3 trial, but the vaccine is still investigational and not yet approved. The study only included healthy volunteers, so results may not apply to people with weakened immune systems.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MENINGOCOCCAL IMMUNISATION (HEALTHY VOLUNTEERS) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Investigational Site Number 3920001
Koganeishi, Japan
-
Investigational Site Number 3920002
Shinjuku-Ku, Japan
-
Investigational Site Number 3920003
Shinjuku-Ku, Japan
-
Investigational Site Number 3920004
Nagoya, Japan
More trials for these conditions
Other studies related to the condition(s) this trial covers.